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Background: Everolimus (EVE) is a drug widely used in several renal transplant protocols. Although characterized by a
relatively low nephrotoxicity, it may induce several adverse effects including severe fibro-interstitial pneumonitis. The
exact molecular/biological mechanism associated to these pro-fibrotic effects is unknown, but epithelial to mesenchymal
transition (EMT) may have a central role. Additionally, heparanase, an enzyme recently associated with the progression of
chronic allograft nephropathy, could contribute to activate this machinery in renal cells.
Methods: Several biomolecular strategies (RT-PCR, immunofluorescence, zymography and migration assay) have been
used to assess the capability of EVE (10, 100, 200 and 500 nM) to induce an in vitro heparanase-mediated EMT in
wild-type (WT) and Heparanase (HPSE)-silenced immortalized human renal epithelial proximal tubular cells (HK-2).
Additionally, microarray technology was used to find additional biological elements involved in EVE-induced EMT.
Results: Biomolecular experiments demonstrated a significant up-regulation (more than 1.5 fold increase) of several
genes encoding for well known EMT markers [(alpha-smooth muscle actin (α-SMA), Vimentin (VIM), Fibronectin (FN) and
matrix metalloproteinase-9 (MMP9)], enhancement of MMP9 protein level and increment of cells motility in WT HK2 cells
treated with high concentrations of EVE (higher than 100 nM). Similarly, immunofluorescence analysis showed that 100
nM of EVE increased α-SMA, VIM and FN protein expression in WT HK2 cells. All these effects were absent in both
HPSE- and AKT-silenced cell lines. AKT is a protein having a central role in EMT. Additionally, microarray analysis identified
other 2 genes significantly up-regulated in 100 nM EVE-treated cells (p < 0.005 and FDR < 5%): transforming growth
factor beta-2 (TGFβ2) and epidermal growth factor receptor (EGFR). Real-time PCR analysis validated microarray.
Conclusions: Our in vitro study reveals new biological/cellular aspects of the pro-fibrotic activity of EVE and it
demonstrates, for the first time, that an heparanase-mediated EMT of renal tubular cells may be activated by high doses
of this drug. Additionally, our results suggest that clinicians should administer the adequate dosage of EVE in order to
increase efficacy and reduce adverse effects. Finally heparanase could be a new potential therapeutic target useful to
prevent/minimize drug-related systemic fibrotic adverse effects.
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Everolimus (EVE) belongs to the group of drugs called
mammalian target of rapamycin inhibitors (mTOR-I), a
group of proliferation signal inhibitors used in several de
novo and maintenance renal transplant immunosuppres-
sive protocols and to treat some tumors [1].* Correspondence: gianluigi.zaza@univr.it
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stated.The main mechanism of action of this drug is the inhib-
ition of mTOR, a regulatory protein kinase involved in
lymphocyte proliferation, developmental processes such as
neurologic and muscle generation, and tumor cell growth
[2,3]. The anticancer efficacy is also correlated to the up-
regulation of adhesion molecules, a switch to less invasive
phenotype of tumoral cells and the inhibition of angiogen-
esis is due to the reduction of vascular endothelial growth
factor production and the decrease of endothelial sensitiv-
ity to such growth factor [4-6]. Additionally, antineoplasticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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talk among mTORC1, mTORC2 and Phosphatidylinositol-
3 kinase (PI3K) [7-9].
Moreover, because of its relative low nephrotoxicity, EVE
is a valid option to calcineurin inhibitors for maintenance
immune suppression in patients with chronic allograft ne-
phropathy [10].
Although it is clear the clinical utility of this drug
category, as other antineoplastic/immunosuppressive
drugs, mTOR-I may induce the development of several
renal (e.g., proteinuria) and systemic side effects includ-
ing hematological disorders (e.g., anemia, leukopenia and
thrombocytopenia), dismetabolism (e.g., hyperlipidemia,
post-transplant diabetes), lymphedema, stomatitis and
fertility/gonadic toxicity [11-13].
In the last years, numerous reports have shown fibrosis-
related pulmonary adverse effects (e.g., lymphocytic inter-
stitial pneumonitis, bronchiolitis obliterans with organizing
pneumonia and focal pulmonary fibrosis) in oncological
and renal transplant patients treated with mTOR-I [13-17].
It is well known that in this clinical condition, epithelial to
mesenchymal transition (EMT) have a pivotal role [18-20].
The EMT is a phenotypic conversion of epithelium to
a fibroblastic or myofibroblastic phenotype. Cells loose
their epithelial proteins and acquire new mesenchymal
markers [including alpha-smooth muscle actin (α-SMA),
vimentin (VIM) and fibronectin (FN)], decrease intercel-
lular adhesion, modify cell polarity and, finally, increase
migratory and invasive properties [21].
Moreover, in renal tissue, during EMT, tubular cells ac-
quire the capacity to migrate into the interstitium through
the degradation of basement membrane [22,23]. This event
is sustained by the release of matrix metalloproteinases
(MMPs) [24,25] and heparanase (HPSE) [26-28], an endo-
glycosidase that cleaves heparan sulphate chains involved
in the pathogenesis of several proteinuric nephropathies
[29,30] and onset of chronic allograft dysfunction [31].
Although EMT program is not the only biological mech-
anism involved in the myofibroblast genesis in renal tissue
[32,33], it could represent a substantial portion of the pro-
fibrotic machinery induced by EVE.
Therefore, the aim of our study has been to analyze
whether EVE (10, 100, 200 and 500 nM) was able to induce
in vitro EMT in immortalized human tubular epithelial
cells (HK2) and to assess the relative contribution of HPSE
to this biological effect. Additionally, it could be useful to
better understand the complex cellular machinery associ-
ated with the onset of renal or systemic fibrosis-related ad-
verse effects following the administration of this drug.
Material and methods
Cell cultures, HPSE and AKT silencing and treatments
Everolimus was kindly provided by Novartis (Basel,
Switzerland) and dissolved in DMSO according to themanufacturer’s instructions. Clonal human derived renal
proximal tubule (HK-2) cells were grown in DMEM-F12
(EuroClone) (17.5 mM glucose) supplemented with 10%
fetal bovine serum (Sigma Aldrich), 2 mM L-glutamine,
penicillin (100 U/ml) and streptomycin (100 μg/ml)
and maintained at 37°C in a 5% CO2 water-saturated
atmosphere.
A stably HPSE-silenced HK-2 cell line was obtained by
transfection with shRNA plasmid targeting human HPSE
(NM_006665) purchased from OriGene, as previously
described [27]. HPSE-silenced HK-2 cells (shHPSE) were
grown in the same medium of wild-type (WT) HK-2 cells.
Cells (WT and shHPSE) were grown to sub-confluence,
starved in serum-free medium for 24 hours and then cul-
tured in serum-free medium with 10, 100, 200 and 500
nM EVE for 6 hours. Fibroblast growth factor-2 (FGF-2), a
growth factor that induces EMT was used as positive con-
trol. Control cultures were incubated with DMSO alone.
AKT1/2 small interfering RNA (siRNA) (sc43609, Santa
Cruz Biotechnology Heidelberg, Germany) has been used
to specifically silence AKT1 and AKT2 (see Additional
file 1: Supplemental method and Additional file 2:
Figure S1). HK2 WT cells were seeded into 6-well plates
at a density of 1.5 × 105 cells per well in 2 ml complete
growth medium. After 24 h, the siRNA was added in
serum-free medium. After 24 h the medium was replaced
with fresh complete growth medium. Cells were incubated
for an additional 24 h and then starved, treated with EVE
(10 and 100 nM) and assayed for gene expression.
RNA expression analysis of HPSE, α-SMA, FN, VIM
and MMP-9
Total RNA was extracted from the cell monolayer
using the GenElute Mammalian Total RNA Miniprep
kit (Sigma-Aldrich) including DNase treatment (DNase70;
Sigma). Yield and purity were assessed using Nanodrop
(EuroClone) and Agilent 2100 Bioanalyzer, respectively.
Total RNA from each sample was reverse-transcribed into
cDNA using SuperScript II reverse transcriptase (Invitro-
gen). Real-time PCR were performed on an ABI-Prism
7500 using Power SYBR Green Master Mix 2 (Applied
Biosystems). A quantitative analysis was performed to eval-
uate the expression of HPSE, MMP-9, α-SMA, VIM, FN,
TGFβ2 and EGFR normalized to GAPDH. The com-
parative Ct method (ΔΔCt) was used to quantify gene
expression, and the relative quantification was calcu-
lated as 2-ΔΔCt. Melting curve analysis was performed
to check for any presence of non-specific amplification
products.
Immunofluorescence for α-SMA, VIM and FN
WT and HPSE-silenced cells were seeded in 22-mm glass
dishes and cultured to subconfluence, serum-starved for
24 h, and then incubated with or without EVE for 24 h to
Figure 1 Heparanase (HPSE) silencing efficiency evaluated by
RT-PCR. Histogram represents the relative HPSE gene expression in
wild-type (WT) and HPSE-silenced (shHPSE) cell lines. The very low
HPSE level in shHPSE demonstrates the good efficiency of cellular
silencing procedure. **p < 0.001 versus WT.
Masola et al. Journal of Translational Medicine 2013, 11:292 Page 3 of 12
http://www.translational-medicine.com/content/11/1/292analyze α-SMA, VIM and FN protein expression. Cells
were fixed in 4% paraformaldehyde and permeabilized in
phosphate-buffered saline (PBS) + 0.2% Triton-×100. Cells
were incubated with primary antibodies for α-SMA (mouse
anti-α-smooth muscle actin, 1A4, Sigma), VIM (Monoclo-
nal Mouse Anti-Vimentin, Clone V9, Dako) and FN (Anti-
Fibronectin antibody [IST-9] ab6328, abcam) overnight at
4°C in PBS with 1% BSA, then washed three times for
5 min with PBS before incubating them for 1 h at 37°C
with the secondary antibody (goat anti-mouse IgG-FITC;
Millipore) in PBS with 1% BSA. Nuclei were counter-
stained with Hoechst 33258.
Zymography for MMP9
Gelatin substrate zymography was used to assess MMP9
activity in WT and shHPSE HK-2 cell conditioned media.
Conditioned media were prepared by incubating sub-
confluent cells in serum-free medium for 24 h, then with
EVE at different dosages for a further 24 h. Equal amounts
of conditioned media were resolved in non reducing sam-
ple buffer on 10% SDS-polyacrylamide gels co-polymerized
with 0.1% gelatin. After electrophoresis, the gels were
washed twice for 30 min in 2.5% Triton X-100 at room
temperature to remove SDS, then equilibrated for 30 min
in collagenase buffer and finally incubated overnight with
fresh collagenase buffer at 37°C. After incubation, gels were
stained in 0.1% Coomassie Brilliant Blue R-250, 30%
MetOH/10% acetic acid for 1 h and destained in 30%
MetOH/10% acetic acid. Digestion bands were analyzed
using ImageJ software.
Migration assay
Briefly, a denuded area was generated on a quiescent cell
monolayer of HK-2 cells by scratching with a sterile pip-
ette tip. The monolayer was washed twice with PBS and
then incubated with medium containing the drug. Each
experimental condition was tested in triplicates. The cells
were photographed at different time points. The scratch
area was measured in each photo to obtain a mean value.
Migration was reported as the difference (in mm2) be-
tween the scratch dimensions observed at the baseline
and after 24 hours.
Microarray analysis
For microarray analysis we used only cells treated with
100 nM EVE because it was the lowest concentration able
to trigger EMT phenotypic changes in our HK2 cells.
Then, the labeled complementary RNA (cRNA) was pro-
duced using the Low Input Quick Amp Labeling (LIQA)
kit (Agilent Technologies), and hybridized for 17 hours at
65°C on the Agilent SurePrint G3 Human GE 8x60K
Microarray slide (Agilent Technologies). In particular it
comprises more than 41,000 features, representing 34,127
human Entrez Gene RNAs. After hybridization the slideswere washed according to Agilent protocols and finally
scanned using the High-Resolution Microarray C Scanner
(Agilent Technologies). The image files obtained by this
procedure were processed using the Agilent Feature Ex-
traction software (v10.7.3).
Statistical analysis
Mean ± S.D. of the real-time PCR data were calculated
with Rest2009 software. Differences between WT and
HPSE-silenced cells, or between pre- and post-EVE treat-
ment, were compared using Two-tailed Student’s t-test. A p
value < 0.05 was set as the level of significance for all tests.
For microarray analysis, we selected, according to Groger
CJ et al. [34], a total of 115 gene probe sets (corresponding
to 83 genes) involved in EMT. The preprocessed micro-
array data were imported into the R language for statistical
analysis computing (http://www.r-project.org). Genes dis-
playing differential expression between pre and post-EVE
treatment were detected using a t-test. Gene probe sets
were sorted after significant p-value and were adjusted to
account for multiple testing using the FDR method of
Storey and Tibshirani [35].
Results
Everolimus-induced matrix metalloproteinase 9 (MMP9)
gene expression
To evaluate whether EVE treatment was able to modu-
late MMP9 transcription in wild-type (WT) and HPSE-
silenced HK-2 cells (shHPSE) [Figure 1], we first treated
for 6 hours both cell lines with EVE (10, 100, 200 and
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in EMT and, then, we measured MMP9 gene expression
by real-time PCR.
As showed in Figure 2A, only high EVE dosages (100,
200 and 500 nM) significantly increased the MMP9 ex-
pression level, while 10 nM EVE (corresponding to thera-
peutic concentration) did not induce any modulation of
this EMT marker.
Otherwise, in shHPSE cells, EVE did not induce any
change in the expression level of this proteinase.
MMP9 Activity after everolimus treatment
To assess if the MMP9 protein level mirrors the increased
mRNA expression, we measured the extracellular MMP9Figure 2 Matrix metalloproteinase-9 (MMP9) gene expression and activ
mRNA expression levels determined by real-time PCR in WT and HPSE silence
100, 200 and 500 nM Everolimus for 6 h. FGF-2 (10 ng/ml), a well-known EMT
separate experiments performed in triplicate. *p < 0.05 vs WT control cells (CT
MMP-9 activity bands in the serum-free conditioned media of WT and silence
and 500 nM Everolimus for 24 h, then conditioned media were harvested. Low
activity. Mean ± S.D. (error bars) of three separate experiments performed in tactivity by gelatin zymography on conditioned media of
WT and shHPSE cells. Our data showed, similarly to RT-
PCR, that only high EVE dosages (100, 200 and 500 nM)
significantly triggered the release of active MMP9 by WT
tubular cells, whereas this drug had no effect on HPSE-
Silenced cells [Figure 2B]. No effects were observed in
both cell lines after incubation with 10 nM EVE.Alpha-SMA (αSMA), vimentin (VIM) and fibronectin (FN)
gene expression
Subsequently, to better define EVE-induced EMT, we
measured the expression level of other three well known
EMT markers: αSMA, VIM and FN.ity after Everolimus (EVE) treatment. (A) Histograms represent MMP9
d HK-2 cells (shHPSE). WT and silenced cell lines were cultured with 10,
inducer, was used as positive control. Mean ± S.D. (error bars) of three
R); **p < 0.001 versus WT CTR. (B) Upper, gelatin zymography shows
d HK2 cells. WT and silenced cell lines were cultured with 10, 100, 200
er, histogram represents the densitometric analysis of relative MMP-9
riplicate. *p < 0.05 vs WT control cells (CTR); **p < 0.001 versus WT CTR.
Figure 3 Alpha-SMA (α-SMA) Vimentin (VIM) and Fibronectin (FN)
gene expression after Everolimus (EVE). Histograms represent
A) α-SMA, B) VIM and C) FN mRNA levels determined by real-time PCR.
WT and silenced cell lines were cultured with Everolimus (10, 100, 200
and 500 nM) for 6 h. FGF-2 (10 ng/ml) was used as positive control.
Mean ± S.D. (error bars) of three separate experiments performed in
triplicate. *p < 0.05 vs WT control cells (CTR); **p < 0.001 versus WT CTR.
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to FGF-2 (10 ng/ml), increased α-SMA, VIM and FN ex-
pression level in WT tubular cells. One-hundred nM
EVE induced a significant α-SMA and FN up-regulation,
but it was unable to determine a change in the VIM ex-
pression level. Similarly to MMP9, we did not observe
any EVE-induced gene expression modulation of these
markers in HPSE shRNA cells.
Moreover, 10 nM EVE did not induce any change in
αSMA, VIM and FN expression levels [Figure 3].
Immunofluorescence (IF) analysis
Conformingly to RT-PCR experiments, IF analysis showed
that high concentration of EVE (100 nM) increased protein
expression of α-SMA, VIM and FN in WT HK2 cells. No
effects were seen in HPSE-silenced cells. Additionally, cells
treated with 10 nM EVE did not show any change in the
protein expression of the above mentioned mesenchymal
markers [Figure 4].
Cell motility
During EMT, renal tubular epithelial cells acquire the abil-
ity to migrate through the basal membrane into the inter-
stitium. We showed that only high EVE doses were able
to induce significant cell motility in WT cells. HPSE si-
lenced cells did not show this property. EVE 10 nM was
unable to determine also this biological effect [Figure 5].
This result suggests that the therapeutic dosage of EVE
does not induce EMT.
Role of AKT
Since mTORC1 inhibition may lead to AKT activation
and since AKT pathway has a central role in EMT, we
investigated the effect of EVE in AKT-silenced cells.
Silencing of AKT did not modify α-SMA, VIM, FN and
MMP9 basal expression levels but prevented their in-
crease in response to 100 nM EVE [Figure 6].
Microarray
In order to confirm results obtained by classical bio-
molecular techniques and to find new biological elements
involved in EVE-induced EMT, we analyzed the differences
in expression of 83 EMT-related genes in HK-2 cells be-
tween pre- and post-EVE treatment. Interestingly, after
statistical analysis, we identified other 2 genes significantly
up-regulated in EVE-treated cells (p < 0.005 and FDR < 5%):
transforming growth factor beta 2 (TGFβ2) and epidermal
growth factor receptor (EGFR) [Figure 7A and B]. Gene
expression analysis by real-time PCR confirmed the afore-
mentioned results [Figure 7C and D]. Additionally, α-SMA,
VIM, FN and MMP9 mRNA levels were higher in EVE-
treated cells compared to CTR confirming our previous
results (see Additional file 3: Figure S2).Discussion
Since the introduction in renal transplant therapy, mTOR
inhibitors (mTOR-I, Sirolimus and Everolimus) have been
considered promising immunosuppressant due to their
relatively low nephrotoxicity [36,37]. The main mechan-
ism of action of these drugs is the inhibition of cell signal-
ing through the PI3K/Akt/mTOR pathway [38-40].
mTOR is a large protein belonging to the phosphoino-
sitide kinase-related kinase family. The carboxy-terminal
Figure 4 Alpha-SMA (α-SMA), Vimentin (VIM) and Fibronectin (FN) protein expression after Everolimus (EVE). Representative images
of one of two immunostaining experiments for α-SMA, VIM and FN in WT and HPSE-silenced cells, with or without EVE treatment
(magnification, ×400).
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rapamycin binding (FRB) domain. In mammals, mTOR
associates with mammalian lethal with SEC13 protein 8
(mLST8), proline-rich AKT substrate of 40 kDa (AKT1S1)
and regulatory-associated protein of mTOR (RAPTOR)
to form the rapamycin-sensitive mTOR complex 1 (mTO
RC1). The mTORC1 activates protein synthesis through
modulation of the 40S ribosomal protein S6 kinase (S6K)and the translational initiation factor eIF-4E binding pro-
tein 1 (4E-BP1). mTORC1 is acutely sensitive to inhibition
by Sirolimus/Everolimus. Both drugs interact in mam-
malian cells with the immunophilin FKBP12, and the
FKBP12–rapamycin complex then binds to the FRB do-
main in mTOR. On docking to the FRB domain, which
is in close proximity to the catalytic site, the FKBP12–
rapamycin complex allosterically inhibits mTORC1 kinase
Figure 5 Cell migration induced by Everolimus (EVE). Histogram represents migration (in mm2) over 24 h in WT and silenced cell lines after
treatment with Everolimus (10, 100, 200 and 500 nM). Data are presented as mean ± S.D. (error bars) of three separate experiments. *p < 0.05 vs
WT control cells (CTR).
Figure 6 α-SMA, VIM, FN and MMP9 expression in WT and AKT-silenced cells treated with EVE. Histograms represent A) α-SMA, B) VIM,
C) FN and D) MMP9 mRNA expression levels determined by real-time PCR. WT and AKT-silenced cells were cultured with Everolimus (10 and 100 nM)
for 6 h. Mean ± S.D. (error bars) of three separate experiments performed in triplicate. **p < 0.001 versus WT CTR.
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Figure 7 Up-regulated genes in HK2 cells after 100 nM EVE treatment. Histogram represents the normalized expression level of TGFβ2 (A) and
EGFR (B) in un-treated (CTR) and EVE-treated HK2 cells (EVE 100 nM) determined by microarray. P value performed by two-sample t-test. Histograms
C and D represent, respectively, TGFβ2 and EGFR mRNA expression levels determined by real-time PCR. WT cells were cultured with 100 nM Everolimus
for 6 h. Mean ± S.D. (error bars) of three separate experiments performed in triplicate. P value was calculated by two-sample t-test.
Masola et al. Journal of Translational Medicine 2013, 11:292 Page 8 of 12
http://www.translational-medicine.com/content/11/1/292activity by an unknown mechanism [41]. These biological
effects confer to these drugs important immunosuppres-
sive and anti-proliferative properties.
Despite this potential, numerous published reports have
described important EVE-related adverse effects in organ
transplant recipients (e.g., impaired wound healing, in-
creased risk of dyslipidemia, proteinuria and prolonged re-
covery of delayed graft function) [11-13].
Particularly, in the last years, there have been described
several interstitial pulmonary fibrosis events following mT
OR-I administration [13-17]. Although, the ethiopathoge-
netic mechanism associated to these pulmonary diseases is
still not completely defined, the activation of a partial EMT
in bronchial epithelial cells treated with mTOR-I seems to
have a pivotal role [18-20]. These cells, in fact, showed
higher protein expression of mesenchymal markers includ-
ing fibronectin and vimentin [19].
Therefore, to evaluate whether EVE treatment was able
to induce EMT in human proximal tubular (HK-2) cells,
we measured, by RT-PCR, changes in expression level of
four genes encoding for well known EMT markers (MMP-
9, α-SMA, Fibronectin and Vimentin) in wild-type (WT)
and HPSE-silenced HK2 cells incubated for 6 hours with
10, 100, 200 and 500 nM EVE. We chose to test in vitrohigh EVE concentrations (more than 100 nM), because
corresponding to dosage frequently used in chemothera-
peutic protocols.
Our results demonstrated that WT HK-2 cells cultured
with high concentrations of EVE (from 100 to 500 nM)
exhibited an up-regulation of all four EMT markers both
at gene and protein level. Additionally, these dosages in-
duced the increase of MMP-9 enzymatic activity and a sig-
nificant cellular migration in the same cell lines.
On the other side, low dose of EVE (10 nM), usually used
for organ transplantation, was unable to induce EMT in
WT cells. This is in line with several published papers
reporting potential anti-fibrotic kidney properties of both
mTOR-I [42,43]. Pontrelli et al. have recently reported that
rapamycin, reducing Plasminogen activator inhibitor-1
(PAI)-1 expression, was able to decrease extracellular
matrix (ECM) deposition in all renal compartments of
patients with chronic allograft nephropathy [44].
On the other hand, high concentrations of EVE, through
a massive mTORC1 inhibition, may lead to a down-
regulation of S6K and a subsequent hyper-activation of
mTORC2 that, sustaining the phosphorylation of AKT at
S473, could induce a feedback loop that stimulates PI3K-
AKT signaling activating the cellular/molecular machinery
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activated, could induce, through the inhibition of Glycogen
synthase kinase 3 (GSK3), the nuclear translocation of β-
catenin which stimulates the expression of EMT-associated
genes [49] [Figure 8]. Our data confirmed that the knock-
down of AKTcan control the activation of EMT program.
This confirms previous results from pharmacodynamic
analysis of cancer patient–derived tumor material showed
increased AKT S473 phosphorylation in some cases [50,51]
after treatment with doses and schedules of EVE defined as
biologically optimal through pharmacokinetic/pharmacody-
namic modeling of preclinical and phase I data [52-54].
Additionally, we emphasized that, as previously dem-
onstrated, HPSE has a pivotal role in the aforementioned
pathway [27,28]. In fact, the silencing of this enzyme in
our cellular model reversed the activation of the EMT
[55,56].
Heparanase (HPSE) is an endo-β-D-glucuronidase that
cleaves heparan sulfate (HS) side chains at a limited
number of sites, hence participates in ECM degradation
and remodeling [57,58]. The degradation of several con-
stituents of the ECM, including heparan sulfate proteo-
glycans (HSPG), promotes the release of growth factors
such as FGF-2. Moreover, we previously shown that HPSE
is necessary to sustain the PI3K/AKT pathway mediated
by FGF-2 which induces the expression of mesenchymalFigure 8 Supposed mechanism of EVE-induced EMT. The treatment wi
It is known that mTORC2 complex participates in AKT activation (S473 pho
Therefore, high concentrations of EVE, through a massive mTORC1 inhibition, m
mTORC2 that, sustaining the phosphorylation of AKT at S473, could induce a fee
molecular machinery leading to renal fibrosis. In particular AKT, once activated, c
β-catenin which stimulates the expression of EMT-associated genes.markers α-SMA and Vimentin (VIM), leads to degrad-
ation of the basement membrane by means of the secre-
tion of matrix metalloproteinases (MMPs) and increases
cell motility [26]. The heparanase expression is finely reg-
ulated by transcription factor, DNA methylation and vari-
ous endogenous molecules [59-61].
Finally in order to find new elements involved in EVE-
induced EMT, we analyzed the differences in the tran-
scriptomic profile (83 EMT-related genes) between HK-2
EVE-treated cells and controls. Our study was performed
using a microarray technology able to evaluate simultan-
eously the expression of more than 30,000 genes. How-
ever, to take full advantage of the opportunities offered by
this high throughput method, it is necessary to manage,
integrate and interpret a huge amount of data correctly.
Thus, we decided to use a pathway analysis to focus our
research on candidate genes known to be associated with
EMT in order to reduce the false positive rate and the
puzzling factors not directly associated with the aims of
our research.
Different statistical algorithms identified two genes (TG
Fβ2 and EGFR) significantly up-regulated by this drug.
Transforming growth factor-beta 2 (TGF-β2) is a se-
creted signaling molecule that regulates a diverse range
of cellular responses, including proliferation, differenti-
ation, migration and apoptosis [62]. Even if the TGF-β1th high doses of Everolimus activates the EMT pathway in tubular cells.
sphorylation) and AKT is a central signal pathway in renal EMT.
ay lead to a down-regulation of S6K and a subsequent hyper-activation of
dback loop that stimulates PI3K-AKT signaling activating the cellular/
ould induce, through the inhibition of GSK3, the nuclear translocation of
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kidney, also TGF-β2 is a well defined key mediator of
EMT-induced fibrosis in both experimental and human
kidney diseases [63-66].
Epidermal growth factor receptor (EGFR) is a trans-
membrane protein receptor with tyrosine kinase activity
that triggers numerous signaling pathways involved in di-
verse cell functions (e.g., proliferation, cell survival) and it
has been recently considered a key role of EGFR in TGFβ-
dependent tubulointerstitial EMT-induced fibrosis [67].
Interestingly, although renal EMT-related effects were
reached in our model only with very high concentration
of this drug, we can not exclude that other different cells
(including pneumocytes, bronchial epithelium cells) or pa-
tients with a genetic predisposition could present this con-
dition after exposure to lower or therapeutic dose of EVE.
This assumption is in line with a recent work published
by Xu X et al. describing a pro-fibrotic effect of mTOR in-
hibitors in lung epithelial cells [68]. However, our hypoth-
esis, although suggestive, need to be better addressed and
validated in future in vivo studies.
Finally, our results, if confirmed by additional studies,
could be useful for researchers to develop new therapeutic
strategy that may prevent/minimize the systemic fibrotic
adverse effects induced by EVE therapy.
Altogether, our data, although obtained by an in vitro
model, reveal new biological/cellular aspects of the renal
and systemic pro-fibrotic machinery induced by EVE
treatment.Conclusions
Our in vitro study reveals new biological/cellular aspects
of the pro-fibrotic activity of EVE and it demonstrates,
for the first time, that an heparanase-mediated EMT in
renal tubular cells may be activated by high doses of this
drug. Additionally, our results, confirming several litera-
ture evidences [69], suggest that clinicians should adminis-
ter the adequate dosage of EVE in order to increase
efficacy and reduce adverse effects. Finally HPSE could be
a new potential therapeutic target useful to prevent/
minimize mTOR-I-related systemic fibrotic adverse effects.Additional files
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